Original Article
Brief Report
The Development of Vancomycin Resistance in a Patient with Methicillin-Resistant Staphylococcus aureus Infection
N Engl J Med 1999; 340:517-523February 18, 1999
- Article
Over the past two decades, vancomycin has been considered the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Indeed, multidrug-resistant clones of MRSA for which the only available effective antibacterial agent is vancomycin have recently been identified. Recent reports describing the therapeutic failure of vancomycin for MRSA infections have aroused considerable concern regarding the emergence of MRSA strains for which there will be no effective therapy.1-3 The mechanism of reduced susceptibility in these staphylococcal strains has not been identified, although data indicate that it is not the same as the vancomycin-resistance mechanism in enterococcal strains.4
We describe here microbiologic properties of MRSA strains recently isolated from a patient receiving vancomycin therapy. The last of the three isolates, recovered shortly before the patient's death, showed resistance to vancomycin.
Case Report
A 79-year-old man with end-stage renal disease due to hypertension began hemodialysis in August 1996. In November and December 1997, repeated thrombosis of his arteriovenous Gore-Tex graft occurred, and on December 15 an internal jugular catheter was inserted. On December 31, 1997, he was admitted to the hospital with fever and altered mental status, and both of two blood cultures were positive for MRSA. One gram of vancomycin had been given intravenously at the outpatient dialysis center three hours before these positive blood-culture results were obtained. He had also received 1 g of intravenous vancomycin 12 months and again 6 weeks before this admission, when thrombectomies of the arteriovenous graft were performed. He received 500 mg of vancomycin intravenously on days 2 and 4 of this admission and twice weekly thereafter. A culture of blood taken four days after admission was negative. The internal jugular catheter broke and was removed on January 10, 1998; cultures of the catheter tip were positive for MRSA. The atrioventricular graft became thrombosed, and a new graft was inserted on January 20. The original graft, however, was left in place. The patient was discharged on January 30, 1998, and continued to receive 500 mg of vancomycin intravenously twice weekly until February 13, 1998. During therapy, the concentration of vancomycin in five random serum samples ranged from 6.3 to 17.3 μg per milliliter.
The patient was readmitted on March 20, 1998, with fever (temperature, 40°C), altered mental status, and shortness of breath. Blood cultures on admission were positive for MRSA. Intravenous vancomycin, tobramycin and ceftriaxone were administered, but he died the next day. An autopsy was not performed.
Methods
Bacterial strains used in this study and their relevant properties are listed in Table 1Table 1
Properties of MRSA Strains.. Species present in the isolates were identified with use of the API-Staph Test System (BioMerieux Vitek, Hazelwood, Mo.). Tryptic soy broth and tryptic soy agar (Difco, Detroit) were used for the cultivation and analysis of bacterial cultures, which were grown at 37°C with vigorous aeration. The antibiotics used were oxacillin, nafcillin, cefazolin, cefotaxime, gentamicin, clindamycin, erythromycin, ciprofloxacin, and vancomycin (obtained from various manufacturers).Chromosomal DNA was prepared and digested with the SmaI endonuclease (New England Biolabs, Beverly, Mass.), and the DNA fragments were separated by pulsed-field gel electrophoresis with a CHEF-DRII apparatus (Bio-Rad, Hercules, Calif.), as described previously.7
Testing for Susceptibility to Antimicrobial Agents
Susceptibility to antibiotics was determined by broth dilution and, in the case of vancomycin and β-lactam antibiotics, by population analysis8 as well. In the population-analysis method, bacterial cultures grown overnight with aeration (≥109 colony-forming units per milliliter) were plated at several dilutions each on a set of tryptic-soy-agar plates containing serial dilutions of the test antibiotic. Plates were incubated at 37°C for 48 hours, and the bacterial colonies were then counted. Plotting colony counts against drug concentrations provided a graphic representation (a population-analysis profile) of the composition of the bacterial culture in relation to the homogeneity or heterogeneity of the antibiotic-susceptibility phenotype. The minimal inhibitory concentration was defined as the lowest concentration of the antibiotic that prevented the appearance of 99.9 percent of the bacterial colonies.
Characterization of Vancomycin-Resistant Isolates
Morphologic changes in the vancomycin-resistant isolates grown in the presence of vancomycin were assessed by phase-contrast microscopy and thin-section electron microscopy, as described previously.9 Induction of autolysis was measured with Triton X-100,10 and the concentration of vancomycin in the growth medium was determined by bioassay.10 The stability of vancomycin resistance was determined by serial culture (passage) of the bacteria for more than 70 generations in drug-free culture medium.
Results
Reduced Susceptibility to Vancomycin and Resistance to Other Antibiotics in MRSA Strain PC-3
MRSA isolates labeled PC-1 and PC-2 were recovered from this patient on December 31, 1997, and January 10, 1998. The clinical sources of PC-1 and PC-2 were blood and the site of catheter exit, respectively. MRSA isolate PC-3 was recovered from blood on March 20, 1998, the day before the patient died.
The minimal inhibitory concentrations of vancomycin, as determined by the broth-dilution method and from the population-analysis profiles, were 2 μg per milliliter for PC-1 and PC-2 and 8 μg per milliliter for PC-3 (Figure 1AFigure 1
Susceptibility of MRSA Strains to Vancomycin.). All three of these isolates were resistant to gentamicin, clindamycin, erythromycin, and ciprofloxacin, and all three gave a positive signal with a mecA-specific DNA probe.6 The minimal inhibitory concentrations of oxacillin, as determined by broth dilution, were 3 μg per milliliter for PC-1 and PC-2 and 0.8 μg per milliliter for PC-3. Population-analysis profiles showed that each isolate had heterogeneous resistance to oxacillin (data not shown).Genetic Relatedness of MRSA Isolates PC-1, PC-2, and PC-3
Figure 2Figure 2
Pulsed-Field Gel Electrophoretic Patterns of the Vancomycin-Resistant Isolate PC-3 and MRSA Isolates Recovered in Eight Hospitals in New York City. shows that the SmaI digestion of chromosomal DNA from isolates PC-1, PC-2, and PC-3 produced identical DNA-fingerprint patterns, indicating their genetic identity. This finding and the clinical history of the patient suggest that PC-3 was derived from the earlier isolates PC-1 and PC-2, presumably as a result of in vivo selection during therapy with vancomycin.Selection of Highly Vancomycin-Resistant S. aureus in Vitro
Bacteria capable of growing on agar plates containing vancomycin at a concentration of 8 μg per milliliter were present at a frequency of approximately 10–3 in cultures of strain PC-3. A colony picked from agar containing 8 μg of vancomycin per milliliter (Figure 1A, arrow) was dispersed in broth and used at a low cell concentration (about 100 cells per milliliter) as inoculum to initiate a broth culture that contained no vancomycin. The next day, the culture was turbid with growth and was plated for population analysis (Figure 1A). All the cells in this culture, denoted PC-3*, could grow on agar containing 8 μg per milliliter of vancomycin, and the minimal inhibitory concentration for the majority of the cells in the culture increased to 16 μg per milliliter. The culture of PC-3* remained heterogeneous and contained (at a frequency of approximately 10–5) bacteria capable of growing even on 16 μg of vancomycin per milliliter.
Genetic Relatedness to Strain PC-3 of an MRSA Clone Widely Spread in Metropolitan New York City
The patterns of the three PC isolates on pulsed-field gel electrophoresis were compared with that of a multidrug-resistant MRSA clone that was recently shown to be widely distributed in hospitals in metropolitan New York (the “New York MRSA”).5,6 Figure 2 shows the electrophoretic patterns of representatives of this MRSA that were recovered in eight hospitals in metropolitan New York. Comparison of the fingerprints clearly showed that the PC isolates were close relatives (subtype variants on pulsed-field gel electrophoresis) of this highly prevalent MRSA clone.
Susceptibility to Vancomycin
We used population analysis to study the susceptibility to vancomycin of MRSA isolates recovered in hospitals in the New York metropolitan area and sharing the pulsed-field electrophoretic type that was closely related to the pattern of our patient's isolates (Figure 1B and Table 1). All the strains examined showed heterogeneous vancomycin-resistance phenotypes. For instance, both strains QNS-2 and WMC-1 contained large subpopulations (frequency, approximately 10–1 and 10–2, respectively) of bacteria that could grow on agar containing 1 μg of vancomycin per milliliter, and bacteria with even higher minimal inhibitory concentrations were also present, at low but measurable frequencies (Figure 1B). A colony of strain NYH-2 picked from the agar plate with 8 μg of vancomycin per milliliter (Figure 1B) and used to inoculate drug-free broth was grown overnight and replated for population analysis. For this strain (NYH-2*), the majority of bacteria had a minimal inhibitory concentration of vancomycin of 8 μg per milliliter, with a population profile similar to that of strain PC-3.
Some Properties of the Vancomycin-Resistant Strain PC-3
Thin sections of PC-3 examined by electron microscopy showed the typical appearance of S. aureus, with no thickening of the cell wall. However, growth of the bacteria in the presence of vancomycin resulted in the formation of multicellular aggregates with large quantities of material on their surface and with staining properties similar to those of cell walls (Figure 3Figure 3
Morphologic Abnormality of the Vancomycin-Resistant Isolate PC-3 Grown in the Presence of Vancomycin.). Measurement of free vancomycin in cultures of PC-3 grown in the presence of 8 μg of the antibiotic per milliliter showed that it gradually decreased in concentration and eventually disappeared from the medium during growth of the bacteria. Vancomycin that disappeared from the medium could then be recovered in its biologically active form from the purified cell walls of PC-3 (Figure 4AFigure 4
High-Performance Liquid Chromatography of Cell Walls of Strain PC-3 Grown in the Presence of Vancomycin. and Figure 4B). In addition, vancomycin inhibited autolysis in PC-3 cultures (data not shown).These properties are similar to those recently observed in a vancomycin-resistant laboratory mutant of an MRSA strain.10 Yet another similarity between the vancomycin-resistant clinical isolate described here and the vancomycin-resistant laboratory mutant VM was the inverse relation between their minimal inhibitory concentrations of vancomycin and methicillin.10 Thus, the minimal concentrations of oxacillin that inhibited the growth of strains PC-1 and PC-2 (minimal inhibitory concentration of vancomycin, 2 μg per milliliter) were 3 μg per milliliter, whereas strain PC-3 (for which a higher concentration of 8 μg of vancomycin per milliliter is required) was inhibited with only 0.8 μg of oxacillin per milliliter.
Effect of Synergistic Combinations of Vancomycin and β-Lactam Antibiotics
Previous observations indicated that inhibitors of early cell-wall synthesis, including vancomycin, can reduce methicillin resistance in MRSA.11 In addition, the minimal inhibitory concentrations of several β-lactam antibiotics were reduced in a highly vancomycin-resistant MRSA strain10 and in strain PC-3 and its derivative PC-3*. On the basis of these findings, we decided to test the effectiveness of combinations of vancomycin and several β-lactam antibiotics.
Figure 5AFigure 5
Inhibition of the Vancomycin-Resistant Strain PC-3* by a Combination of Vancomycin and Oxacillin. and Figure 5B show the effect of a combination of oxacillin and vancomycin on the survival of vancomycin-resistant strain PC-3*, an in vitro derivative of clinical isolate PC-3. The population-analysis profile (Figure 5A) indicates that inclusion of oxacillin at a concentration of 0.4 μg per milliliter, a value below the minimal inhibitory concentration, in the agar plates containing vancomycin caused a significant reduction in the minimal inhibitory concentration of vancomycin, from 16 to 1 μg per milliliter. With vancomycin at a concentration of 16 μg per milliliter or greater in combination with 0.4 μg of oxacillin per milliliter, no surviving colonies of PC-3* could be detected. Figure 5B shows a similar elimination of the vancomycin-resistant S. aureus by the β-lactam–vancomycin combination when vancomycin was incorporated at a constant concentration of 8 μg per milliliter into agar plates containing various concentrations of oxacillin. The minimal inhibitory concentration of oxacillin decreased (from 0.8 to <0.1 μg per milliliter) with the addition of vancomycin to the growth medium. At an oxacillin concentration of 3 μg per milliliter or greater in combination with 8 μg of vancomycin per milliliter, no surviving colonies of PC-3* could be detected. Similar results were obtained when oxacillin was replaced with nafcillin, cefazolin, or cefotaxime.Discussion
There has been concern about the development of vancomycin resistance in multidrug-resistant strains of S. aureus, especially since the demonstration of successful transfer of the vanA gene from enterococci to S. aureus under laboratory conditions.12 Acquisition of the enterococcal vancomycin-resistance mechanism by staphylococci has not yet been observed in clinical isolates. On the other hand, reduced susceptibility to vancomycin has now been described in both Japan and the United States in association with the failure of vancomycin treatment of MRSA infections.1-3 Although the mechanism of staphylococcal resistance to vancomycin is not clear, a mechanism involving alterations in the bacterial cell wall and capture of antibiotic molecules at a distance from the sites of cell-wall synthesis has been proposed on the basis of properties of a vancomycin-resistant laboratory mutant.10 Clearly, elucidation of the mechanism of staphylococcal resistance to vancomycin is urgently needed, since current efforts in drug development are directed against the enterococcal mechanism of vancomycin resistance, which is distinct from that of staphylococci.10
The susceptibility of the MRSA strain PC-3 to vancomycin is similar to those of recently described S. aureus isolates with intermediate levels of vancomycin resistance from hospitals in Japan and the United States.1-3 However, bacteria with minimal inhibitory concentrations of vancomycin as high as 16 μg per milliliter could easily be selected under laboratory conditions by inoculating drug-free growth medium with the more resistant subpopulations. The current experiments demonstrate the relative ease with which bacteria with elevated minimal inhibitory concentrations can take over a culture. The genetic identity among strains PC-1, PC-2, and PC-3 on DNA fingerprinting indicates that such a selection or takeover by the more highly resistant bacteria occurred in vivo, presumably as a consequence of suboptimal therapy with vancomycin in patients with an intravascular foreign body. Our data demonstrate that selection for increased resistance to vancomycin can occur during therapy.
The close genetic relatedness of vancomycin-resistant strain PC-3 to an MRSA clone that is widespread in hospitals in the New York metropolitan area is of obvious concern. On examination, several isolates belonging to this MRSA clone and recovered in eight hospitals did not include isolates associated with a reduced minimal inhibitory concentration of vancomycin similar to that for strain PC-3. However, several of the MRSA isolates from the New York hospitals contained subpopulations of bacteria with minimal inhibitory concentrations of vancomycin greater than those of the majority of cells and surpassing those of strains PC-1 and PC-2. The continued extensive use of vancomycin, together with the possibility of in vivo selection, as demonstrated in the current study, makes surveillance of vancomycin-susceptibility levels in MRSA isolates of primary importance.
Our experiments with the combination of β-lactam antibiotics and vancomycin showed that at easily achievable concentrations such combinations were highly effective against the vancomycin-resistant MRSA strain. No surviving bacteria could be detected after exposure of the vancomycin-resistant strain to a combination of 8 μg of vancomycin and 3 μg of oxacillin per milliliter. It remains to be seen whether this combination of antibiotics is equally effective against other S. aureus isolates with intermediate levels of resistance to vancomycin. If the results of this experiment can be applied to the clinical setting, our data suggest that a combination of vancomycin and commonly available β-lactam agents may be an effective therapeutic regimen against vancomycin-resistant staphylococci.
Supported in part by the Bodman/Achelis Fund, the Cary L. Guy Foundation, and the Glickenhaus Foundation.
We are indebted to Sharon Rotun and staff members of the Clinical Microbiology Laboratory, United Hospital Medical Center, for providing the clinical isolates, and to Marilyn Chung for expert technical assistance.
Source Information
From the Laboratory of Microbiology, Rockefeller University, New York (K.S., R.B.R., A.T.); New York Hospital–Cornell Medical Center, New York (R.B.R.); and United Hospital Medical Center, Port Chester, N.Y. (S.W.H.).
Address reprint requests to Dr. Tomasz at the Laboratory of Microbiology, Rockefeller University, 1230 York Ave., New York, NY 10021, or at tomasz@rockvax.rockefeller.edu.
- References
References
1
Hiramatsu K ,Aritaka N ,Hanaki H , et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-1673
CrossRef | Web of Science | Medline2
Staphylococcus aureus with reduced susceptibility to vancomycin -- United States, 1997
Medline3
Update: Staphylococcus aureus with reduced susceptibility to vancomycin -- United States, 1997
Medline4
Tenover FC ,Lancaster MV ,Hill BC , et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-1027[Erratum, J Clin Microbiol 1998;36:2167.]
Web of Science | Medline5
Roberts RB, de Lencastre A, Eisner W, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in 12 New York hospitals.J Infect Dis 1998;178:164-71.
6
de Lencastre H, Severina EP, Roberts RB, Kreiswirth BN, Tomasz A, BARG Initiative Pilot Study Group
CrossRef | Web of Science | Medline7
de Lencastre H ,Tomasz A . Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1994;38:2590-2598
Web of Science | Medline8
Sieradzki K ,Villari P ,Tomasz A . Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998;42:100-107
Web of Science | Medline9
Tomasz A ,Jamieson JD ,Ottolenghi E . The fine structure of Diplococcus pneumoniae. J Cell Biol 1964;22:453-467
CrossRef | Web of Science | Medline10
Sieradzki K ,Tomasz A . Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-2566
Web of Science | Medline11
Sieradzki K ,Tomasz A . Suppression of β-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 1997;39:Suppl A:47-51
CrossRef | Web of Science | Medline12
Noble WC ,Virani Z ,Cree RGA . Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-198
CrossRef | Web of Science | Medline
- Citing Articles (184)
Citing Articles
1
E. Ahlstrand, K. Svensson, L. Persson, U. Tidefelt, B. Söderquist. (2011) Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. European Journal of Clinical Microbiology & Infectious Diseases 30:11, 1349-1354
CrossRef2
H.- G. Wetzstein, W. Hallenbach. (2011) Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8. Journal of Antimicrobial Chemotherapy
CrossRef3
Zhi Li, Sanjeewa G. Rupasinghe, Mary A. Schuler, Satish K. Nair. (2011) Crystal structure of a phenol-coupling P450 monooxygenase involved in teicoplanin biosynthesis. Proteins: Structure, Function, and Bioinformatics 79:6, 1728-1738
CrossRef4
GongXin Yu, John Bell. (2011) Gnom Cmp : a quantitative approach for comparative analysis of closely related genomes of bacterial pathogens. Genome 54:5, 402-418
CrossRef5
Ahmed H. Salem, Walid F. Elkhatib, Ayman M. Noreddin. (2011) Pharmacodynamic assessment of vancomycin-rifampicin combination against methicillin resistant Staphylococcus aureus biofilm: a parametric response surface analysis. Journal of Pharmacy and Pharmacology 63:1, 73-79
CrossRef6
Vimal Chadha, Franz S. Schaefer, Bradley A. Warady. (2010) Dialysis-associated peritonitis in children. Pediatric Nephrology 25:3, 425-440
CrossRef7
Ritesh P. Bhole, Kishore P. Bhusari. (2010) Synthesis and 3D-QSAR of p-Hydroxybenzohydrazide Derivatives With Antimicrobial Activity Against Multidrug-Resistant Staphylococcus aureus. Journal of the Korean Chemical Society 54:1, 77-87
CrossRef8
Erin H Kil, Jeffrey M Weinberg. (2010) Methicillin-resistant Staphylococcus aureus : an update for the dermatologist. Expert Review of Dermatology 5:1, 45-60
CrossRef9
M. Osińska-Jaroszuk, G. Ginalska, A. Belcarz, A. Uryniak. (2009) Vascular Prostheses with Covalently Bound Gentamicin and Amikacin Reveal Superior Antibacterial Properties than Silver-impregnated Ones – An In Vitro Study. European Journal of Vascular and Endovascular Surgery 38:6, 697-706
CrossRef10
Dahlene N. Fusco, Elizabeth L. Alexander, Scott A. Weisenberg, Jose R. Mediavilla, Barry N. Kreiswirth, Audrey N. Schuetz, Stephen G. Jenkins, Kyu Y. Rhee. (2009) Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus. Diagnostic Microbiology and Infectious Disease 65:2, 180-183
CrossRef11
Reena Lamichhane-Khadka, Stephanie A. Cantore, James T. Riordan, Alejandro Delgado, Alesha E.A. Norman, Sarah Dueñas, Shahrear Zaman, Sonia Horan, Brian J. Wilkinson, John E. Gustafson. (2009) sarA inactivation reduces vancomycin-intermediate and ciprofloxacin resistance expression by Staphylococcus aureus. International Journal of Antimicrobial Agents 34:2, 136-141
CrossRef12
Howard S. Gold, Satish K. Pillai. (2009) Antistaphylococcal Agents. Infectious Disease Clinics of North America 23:1, 99-131
CrossRef13
Kumiko NODA, Akira UEDA, Hiroshi KURONUMA, Shinji IWAI, Katsumi ITO, Yoko SAITOH, Shigeaki OGURA, Michiya KOBAYASHI, Koji TADANO. (2009) Japanese Journal of Environmental Infections 24:5, 332-336
CrossRef14
Paul A. Majcherczyk, Jean-Luc Barblan, Philippe Moreillon, José M. Entenza. (2008) Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis. Microbial Pathogenesis 45:5-6, 408-414
CrossRef15
Kittisak Chawawisit, Monthon Lertcanawanichakul. (2008) Minimum inhibitory concentration (MIC) of crude preparations of Brevibacillus laterosporus SA14 bioactive material compared to vancomycin and oxacillin, against clinical isolates of methicillin-resistant Staphylococcus aureus. World Journal of Microbiology and Biotechnology 24:10, 2199-2204
CrossRef16
Andrew M Roecker, Scott D Pope. (2008) Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opinion on Pharmacotherapy 9:10, 1745-1754
CrossRef17
J. Chastre. (2008) Evolving problems with resistant pathogens. Clinical Microbiology and Infection 14:s3, 3-14
CrossRef18
M. Kandhasamy ., K.D. Arunachalam .. (2008) In vitro Antibacterial Activity of Tuber Extracts of Zhenaria scabra. Journal of Plant Sciences 3:3, 224-229
CrossRef19
Tomoko Oshiro, Zenzo Nagasawa, Hideaki Hanaki, Yurika Ikeda-Dantsuji, Ariaki Nagayama. (2008) The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin. Journal of Infection and Chemotherapy 14:1, 15-22
CrossRef20
Thiago Lisboa, Jordi Rello. (2008) Neumonía nosocomial por grampositivos. Enfermedades Infecciosas y Microbiología Clínica 26, 53-60
CrossRef21
Carlos Pigrau, José Barberán. (2008) Infecciones de piel y partes blandas por grampositivos multirresistentes. Enfermedades Infecciosas y Microbiología Clínica 26, 21-30
CrossRef22
H. H. Balkhy, Z. A. Memish, M. A. Almuneef, G. C. Cunningham, C. Francis, K. C. Fong, Z. B. Nazeer, E. Tannous. (2007) Methicillin‐Resistant Staphylococcus aureus: A 5‐Year Review of Surveillance Data in a Tertiary Care Hospital in Saudi Arabia • . Infection Control and Hospital Epidemiology 28:8, 976-982
CrossRef23
Anna M. Ferrara. (2007) Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 30:1, 19-24
CrossRef24
S. Raju, R. Kelmani Chandrakanth, S. A. Patil. (2007) High-Level Oxacillin and Gentamycin Resistance with Reduced Susceptibility to Vancomycin in Staphylococcus aureus-Carrying mecA and femA Gene Complex. Current Microbiology 54:6, 429-434
CrossRef25
Scott D Pope, Andrew M Roecker. (2007) Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opinion on Pharmacotherapy 8:9, 1245-1261
CrossRef26
M. M. Mwangi, S. W. Wu, Y. Zhou, K. Sieradzki, H. de Lencastre, P. Richardson, D. Bruce, E. Rubin, E. Myers, E. D. Siggia, A. Tomasz. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proceedings of the National Academy of Sciences 104:22, 9451-9456
CrossRef27
Michael Vercillo, Michael J Patzakis, Paul Holtom, Charalampos G Zalavras. (2007) Linezolid in the Treatment of Implant-related Chronic Osteomyelitis. Clinical Orthopaedics and Related Research PAP,
CrossRef28
K. Drlica, X. Zhao. (2007) Mutant Selection Window Hypothesis Updated. Clinical Infectious Diseases 44:5, 681-688
CrossRef29
Marianne McCollum, Sonja V. Sorensen, Larry Z. Liu. (2007) A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clinical Therapeutics 29:3, 469-477
CrossRef30
Richard H Drew. (2007) Emerging Options for Treatment of Invasive, Multidrug-Resistant Staphylococcus aureus Infections. Pharmacotherapy 27:2, 227-249
CrossRef31
ST Hakim, S Arshed, M Iqbal, SG Javaid. (2007) Vancomycin Sensitivity of Staphylococcus Aureus Isolates from Hospital Patients in Karachi, Pakistan. Libyan Journal of Medicine 2:4, 176-179
CrossRef32
M. H. Kollef. (2006) Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?. Clinical Infectious Diseases 43:Supplement 2, S82-S88
CrossRef33
Scott D Pope, Andrew M Roecker. (2006) Dalbavancin: A Novel Lipoglycopeptide Antibacterial. Pharmacotherapy 26:7, 908-918
CrossRef34
Louis B. Rice. (2006) Antimicrobial resistance in gram-positive bacteria. American Journal of Infection Control 34:5, S11-S19
CrossRef35
Marin H. Kollef. (2006) The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. Surgical Infections 7:2, 85-99
CrossRef36
Zeina A. Kanafani, Vance G. Fowler. (2006) Staphylococcus aureus Infections: New Challenges from an Old Pathogen. Enfermedades Infecciosas y Microbiología Clínica 24:3, 182-193
CrossRef37
Ellie Hershberger, Simona F. Oprea, Marcus J. Zervos, Mary K. Hayden, David R. Snydman, John D. Rihs, Robert R. Muder. (2006) Multicenter Evaluation of the In Vitro Susceptibility of Staphylococci to Vancomycin. Infectious Diseases in Clinical Practice 14:2, 89-92
CrossRef38
P. C. Appelbaum. (2006) The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 12:s1, 16-23
CrossRef39
Glen T. Hansen, Xilin Zhao, Karl Drlica, Joseph M. Blondeau. (2006) Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 27:2, 120-124
CrossRef40
A. de Lassence, N. Hidri, J.-F. Timsit, M.-L. Joly-Guillou, G. Thiery, A. Boyer, P. Lable, A. Blivet, H. Kalinowski, Y. Martin, J.-P. Lajonchere, D. Dreyfuss. (2006) Control and Outcome of a Large Outbreak of Colonization and Infection with Glycopeptide-Intermediate Staphylococcus aureus in an Intensive Care Unit. Clinical Infectious Diseases 42:2, 170-178
CrossRef41
2006. Vancomycin. , 3593-3606.
CrossRef42
Hitoshi Komatsuzawa, Kazuhisa Ouhara, Sakuo Yamada, Tamaki Fujiwara, Koji Sayama, Koji Hashimoto, Motoyuki Sugai. (2006) Innate defences against methicillin-resistantStaphylococcus aureus (MRSA) infection. The Journal of Pathology 208:2, 249-260
CrossRef43
R. N. Jones. (2006) Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clinical Infectious Diseases 42:Supplement 1, S13-S24
CrossRef44
D. P. Levine. (2006) Vancomycin: A History. Clinical Infectious Diseases 42:Supplement 1, S5-S12
CrossRef45
Abd El-Rahiem A. Ashour ., Zakaria Y. El Astal .. (2005) Antimicrobial Activity of Some Palestinian Medical Plant Extracts: Effect of Crude Extracts and Some of their Subfractions. Pakistan Journal of Biological Sciences 8:11, 1592-1598
CrossRef46
LUIS RUBIO-MARTINEZ, JAVIER LOPEZ-SANROMAN, ANTONIO M. CRUZ, MARTIN SANTOS, FIDEL SAN ROMAN. (2005) Medullary Plasma Pharmacokinetics of Vancomycin After Intravenous and Intraosseous Perfusion of the Proximal Phalanx in Horses. Veterinary Surgery 34:6, 618-624
CrossRef47
M. Wootton, A.P. Macgowan, T.R. Walsh. (2005) Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains. Biochimica et Biophysica Acta (BBA) - General Subjects 1726:3, 326-327
CrossRef48
Tiffany A. Hassen, Robert A. Fitridge. (2005) Infra-inguinal revascularization surgical site infections: Australasian benchmark. ANZ Journal of Surgery 75:11, 967-971
CrossRef49
A ALANIS. (2005) Resistance to Antibiotics: Are We in the Post-Antibiotic Era?. Archives of Medical Research 36:6, 697-705
CrossRef50
T. Katakura, T. Yoshida, M. Kobayashi, D. N. Herndon, F. Suzuki. (2005) Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clinical and Experimental Immunology 0:0, 050929083117003
CrossRef51
C. Ekdahl, H. Hanberger, A. Hällgren, M. Nilsson, E. Svensson, L. E. Nilsson. (2005) Rapid decrease of free vancomycin in dense staphylococcal cultures. European Journal of Clinical Microbiology & Infectious Diseases 24:9, 596-602
CrossRef52
Marin H. Kollef, Scott T. Micek. (2005) Strategies to prevent antimicrobial resistance in the intensive care unit. Critical Care Medicine 33:8, 1845-1853
CrossRef53
Harry G. Preuss, Bobby Echard, Mary Enig, Itzhak Brook, Thomas B. Elliott. (2005) Minimum inhibitory concentrations of herbal essential oils and monolaurin for gram-positive and gram-negative bacteria. Molecular and Cellular Biochemistry 272:1-2, 29-34
CrossRef54
Fred C. Tenover. (2005) The real vancomycin-resistant Staphylococcus aureus has arrived. Clinical Microbiology Newsletter 27:5, 35-40
CrossRef55
B. P. Howden, P. B. Ward, P. D. R. Johnson, P. G. P. Charles, M. L. Grayson. (2005) Low-level vancomycin resistance in Staphylococcus aureus?an Australian perspective. European Journal of Clinical Microbiology & Infectious Diseases 24:2, 100-108
CrossRef56
Michael J. Rybak, Raymond Cha, Chrissy M. Cheung, Venkata G. Meka, Glenn W. Kaatz. (2005) Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diagnostic Microbiology and Infectious Disease 51:2, 119-125
CrossRef57
U. Geipel, M. Herrmann. (2005) Methicillin-resistente Staphylococcus aureus. Der Anaesthesist 54:2, 155-162
CrossRef58
Harry G. Preuss, Bobby Echard, Azad Dadgar, Nadeem Talpur, Vijaya Manohar, Mary Enig, Debasis Bagchi, Cass Ingram. (2005) Effects of Essential Oils and Monolaurin on Staphylococcus aureus : In Vitro and In Vivo Studies. Toxicology Mechanisms and Methods 15:4, 279-285
CrossRef59
Shamez Ladhani, Mehdi Garbash. (2005) Staphylococcal Skin Infections in Children. Pediatric Drugs 7:2, 77-102
CrossRef60
Alejandro Domenech, Sandra Ribes, Carmen Cabellos, M. Angeles Domínguez, Abelardo Montero, Josefina Liñares, Javier Ariza, Francesc Gudiol. (2004) A Mouse Peritonitis Model for the Study of Glycopeptide Efficacy in GISA Infections. Microbial Drug Resistance 10:4, 346-353
CrossRef61
Keith S Kaye, John J Engemann, Henry S Fraimow, Elias Abrutyn. (2004) Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms, and clinical management. Infectious Disease Clinics of North America 18:3, 467-511
CrossRef62
Tammy S Lundstrom, Jack D Sobel. (2004) Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infectious Disease Clinics of North America 18:3, 651-668
CrossRef63
A. Vuagnat, R. Stern, A. Lotthe, H. Schuhmacher, M. Duong, P. Hoffmeyer, L. Bernard. (2004) High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. Journal of Clinical Pharmacy and Therapeutics 29:4, 351-357
CrossRef64
P. A. Moise-Broder, G. Sakoulas, G. M. Eliopoulos, J. J. Schentag, A. Forrest, R. C. Moellering. (2004) Accessory Gene Regulator Group II Polymorphism in Methicillin-Resistant Staphylococcus aureus Is Predictive of Failure of Vancomycin Therapy. Clinical Infectious Diseases 38:12, 1700-1705
CrossRef65
Louis Bernard, Pierre Vaudaux, Peter Rohner, Elzbieta Huggler, Mathieu Armanet, Didier Pittet, Daniel P. Lew, Jacques Schrenzel. (2004) Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains. Journal of Microbiological Methods 57:2, 231-239
CrossRef66
Karl Drlica, Xilin Zhao. (2004) Is ‘dosing-to-cure’ appropriate in the face of antimicrobial resistance?. Reviews in Medical Microbiology 15:2, 73-80
CrossRef67
Marco Cassone, Floriana Campanile, Annalisa Pantosti, Mario Venditti, Stefania Stefani. (2004) Identification of a Variant "Rome Clone" of Methicillin-Resistant Staphylococcus aureus with Decreased Susceptibility to Vancomycin, Responsible for an Outbreak in an Intensive Care Unit. Microbial Drug Resistance 10:1, 43-49
CrossRef68
Marta Aires de Sousa, HermÃnia Lencastre. (2004) Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunology & Medical Microbiology 40:2, 101-111
CrossRef69
Salih Cesur, Fugen Eokca. (2004) Nasal Carriage of Methicillin‐Resistant Staphylococcus aureus Among Hospital Staff and Outpatients • . Infection Control and Hospital Epidemiology 25:2, 169-171
CrossRef70
Didier Lepelletier, Stephanie Perron, Helene Huguenin, Monique Picard, Pascale Bemer, Jocelyne Caillon, Marie‐Emmanuelle Juvin, Henri Bernard Drugeon. (2004) Which Strategies Follow From the Surveillance of Multidrug‐Resistant Bacteria to Strengthen the Control of Their Spread? A French Experience • . Infection Control and Hospital Epidemiology 25:2, 162-164
CrossRef71
Mark Loeb, Allison McGeer, Andrew Simor, Stephen D. Walter, Suzanne Bradley, Donald E. Low, Lorraine Moss. (2004) Facility‐Level Correlates of Antimicrobial Use in Nursing Homes • . Infection Control and Hospital Epidemiology 25:2, 173-176
CrossRef72
Emanuel Goldman. (2004) Antibiotic Abuse in Animal Agriculture: Exacerbating Drug Resistance in Human Pathogens. Human and Ecological Risk Assessment: An International Journal 10:1, 121-134
CrossRef73
Marc‐Oliver Wright, Joan N. Hebden, Anthony D. Harris, Carl B. Shanholtz, Harold C. Standiford, Jon P. Furuno, Eli N. Perencevich. (2004) Aggressive Control Measures for Resistant Acinetobacter baumannii and the Impact on Acquisition of Methicillin‐Resistant Staphylococcus aureus and Vancomycin‐Resistant Enterococcus in a Medical Intensive Care Unit • . Infection Control and Hospital Epidemiology 25:2, 167-168
CrossRef74
Anita Bhalla, Nicole J. Pultz, Delores M. Gries, Amy J. Ray, Elizabeth C. Eckstein, David C. Aron, Curtis J. Donskey. (2004) Acquisition of Nosocomial Pathogens on Hands After Contact With Environmental Surfaces Near Hospitalized Patients • . Infection Control and Hospital Epidemiology 25:2, 164-167
CrossRef75
Rosa V. Rosario‐Rosado, Antonio A. Rene, Bobby Jones. (2004) Descriptive Analysis of Patients With Community‐Onset and Hospital‐Onset Methicillin‐Resistant Staphylococcus aureus Infections • . Infection Control and Hospital Epidemiology 25:2, 171-173
CrossRef76
Pamela A Moise-Broder, Alan Forrest, Mary C Birmingham, Jerome J Schentag. (2004) Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections. Clinical Pharmacokinetics 43:13, 925-942
CrossRef77
Serkan Oncu, Selcen Oncu, Barcin Ozturk, Ibrahim Kurt, Serhan Sakarya. (2004) Elimination of Intraluminal Colonization by Antibiotic Lock in Catheters. The Tohoku Journal of Experimental Medicine 203:1, 1-8
CrossRef78
Marianne McCollum, David C. Rhew, Stephen Parodi. (2003) Cost analysis of switching from IV vancomycin to PO linezolid for the management of methicillin-resistant Staphylococcus species. Clinical Therapeutics 25:12, 3173-3189
CrossRef79
Yoko Takayama, Hideaki Hanaki, Kazuhiko Irinoda, Hideya Kokubun, Kazunari Yoshida, Keisuke Sunakawa. (2003) Investigation of methicillin-resistant Staphylococcus aureus showing reduced vancomycin susceptibility isolated from a patient with infective endocarditis. International Journal of Antimicrobial Agents 22:6, 567-573
CrossRef80
Mark B Loeb, Cheryl Main, Angela Eady, Cindy Walkers-Dilks, Mark B Loeb. 2003. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. .
CrossRef81
J Klastersky. (2003) Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treatment Reviews 29:5, 431-440
CrossRef82
Nina M. Clark, Ellie Hershberger, Marcus J. Zervosc, Joseph P. Lynch. (2003) Antimicrobial resistance among gram-positive organisms in the intensive care unit. Current Opinion in Critical Care 9:5, 403-412
CrossRef83
Patricia Cristofaro, Steven M Opal. (2003) The Toll-like receptors and their role in septic shock. Expert Opinion on Therapeutic Targets 7:5, 603-612
CrossRef84
K. B. Laupland, J. M. Conly. (2003) Treatment of Staphylococcus aureus Colonization and Prophylaxis for Infection with Topical Intranasal Mupirocin: An Evidence-Based Review. Clinical Infectious Diseases 37:7, 933-938
CrossRef85
RAM YOGEV, LORI E. PATTERSON, SHELDON L. KAPLAN, STUART ADLER, MARIA RAYO MORFIN, AMANDO MARTIN, BARBARA EDGE-PADBURY, SHARON NABERHUIS-STEHOUWER, JON B. BRUSS. (2003) Linezolid for the treatment of complicated skin and skin structure infections in children. The Pediatric Infectious Disease Journal 22:Supplement, S172-S177
CrossRef86
SHELDON L. KAPLAN, BEHNOOSH AFGHANI, PIO LOPEZ, ELBA WU, DONA FLEISHAKER, BARBARA EDGE-PADBURY, SHARON NABERHUIS-STEHOUWER, JON B. BRUSS. (2003) Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. The Pediatric Infectious Disease Journal 22:Supplement, S178-S185
CrossRef87
A. Sol
s, D. Brown, J. Hughes, H.K.F. van Saene, D.P. Heaf. (2003) Methicillin-resistantStaphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatric Pulmonology 36:3, 189-195
CrossRef88
Thomas P. Lodise, Peggy S. McKinnon, Michael Rybak. (2003) Prediction Model to Identify Patients With Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance • . Infection Control and Hospital Epidemiology 24:9, 655-661
CrossRef89
Louis Bernard, Pierre Vaudaux, Albert Vuagnat, Richard Stern, Peter Rohner, Didier Pittet, Jacques Schrenzel, Pierre Hoffmeyer, . (2003) Effect of Vancomycin Therapy for Osteomyelitis on Colonization by Methicillin‐Resistant Staphylococcus aureus : Lack of Emergence of Glycopeptide Resistance • . Infection Control and Hospital Epidemiology 24:9, 650-654
CrossRef90
T. S. Naimi, D. Anderson, C. O'Boyle, D. J. Boxrud, S. K. Johnson, F. C. Tenover, R. Lynfield. (2003) Vancomycin-Intermediate Staphylococcus aureus with Phenotypic Susceptibility to Methicillin in a Patient with Recurrent Bacteremia. Clinical Infectious Diseases 36:12, 1609-1612
CrossRef91
Ivo G Boneca, Gabriela Chiosis. (2003) Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opinion on Therapeutic Targets 7:3, 311-328
CrossRef92
Julie Kenner, Tasha O’Connor, Nicholas Piantanida, Joel Fishbain, Bardwell Eberly, Helen Viscount, Catherine Uyehara, Duane Hospenthal. (2003) Rates of Carriage of Methicillin‐Resistant and Methicillin‐Susceptible Staphylococcus aureus in an Outpatient Population • . Infection Control and Hospital Epidemiology 24:6, 439-444
CrossRef93
Franklin D. Lowy. (2003) Antimicrobial resistance: the example of Staphylococcus aureus. Journal of Clinical Investigation 111:9, 1265-1273
CrossRef94
Olivier Denis, Ariane Deplano, Raf De Ryck, Claire Nonhoff, Marc J. Struelens. (2003) Emergence and Spread of Gentamicin-Susceptible Strains of Methicillin-Resistant Staphylococcus aureus in Belgian Hospitals. Microbial Drug Resistance 9:1, 61-71
CrossRef95
Scott K. Fridkin, Jeff Hageman, Linda K. McDougal, Jasmine Mohammed, William R. Jarvis, Trish M. Perl, Fred C. Tenover, . (2003) Epidemiological and Microbiological Characterization of Infections Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin, United States, 1997–2001. Clinical Infectious Diseases 36:4, 429-439
CrossRef96
Thean Yen Tan. (2003) Use of molecular techniques for the detection of antibiotic resistance in bacteria. Expert Review of Molecular Diagnostics 3:1, 93-103
CrossRef97
Simon Gibbons, Moyosoluwa Oluwatuyi, Nigel C. Veitch, Alexander I. Gray. (2003) Bacterial resistance modifying agents from Lycopus europaeus. Phytochemistry 62:1, 83-87
CrossRef98
Franz Schaefer. (2003) Management of Peritonitis in Children Receiving Chronic Peritoneal Dialysis. Pediatric Drugs 5:5, 315-325
CrossRef99
Jeffrey S. Berns. (2003) Infection with Antimicrobial-resistant Microorganisms in Dialysis Patients. Seminars in Dialysis 16:1, 30-37
CrossRef100
Isao Haraga, Shuichi Nomura, Shigeru Fukamachi, Hiroyuki Ohjimi, Hideaki Hanaki, Keiichi Hiramatsu, Ariaki Nagayama. (2002) Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient—importance of low-level resistance to vancomycin. International Journal of Infectious Diseases 6:4, 302-308
CrossRef101
Soumya S. Ray, Jeffrey B. Bonanno, K.R. Rajashankar, Mariana G. Pinho, Guoshun He, Herminia De Lencastre, Alexander Tomasz, Stephen K. Burley. (2002) Cocrystal Structures of Diaminopimelate Decarboxylase. Structure 10:11, 1499-1508
CrossRef102
Timothy R. Walsh, Robin A. Howe. (2002) T
HE PREVALENCE AND MECHANISMS OF VANCOMYCIN RESISTANCE IN STAPHYLOCOCCUS AUREUS . Annual Review of Microbiology 56:1, 657-675
CrossRef103
K. Kondoh, D. Furuya, A. Yagihashi, N. Uehara, M. Nakamura, D. Kobayashi, N. Tsuji, N. Watanabe. (2002) Comparison of arbitrarily primed-polymerase chain reaction and pulse-field gel electrophoresis for characterizing methicillin-resistant Staphylococcus aureus. Letters in Applied Microbiology 35:1, 62-67
CrossRef104
S. Stefani, M. L. Mezzatesta, G. Tempera, E. Debbra, A. M. Schito, G. Nicoletti, A. Marchere. (2002) Comparative activity of linezolid against staphylococci and enterococci isolated in Italy. Clinical Microbiology and Infection 8:6, 368-372
CrossRef105
Dennis L. Stevens, Daniel Herr, Harry Lampiris, John Lee Hunt, Donald H. Batts, Barry Hafkin, . (2002) Linezolid versus Vancomycin for the Treatment of Methicillin‐Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases 34:11, 1481-1490
CrossRef106
P.M Raney, P.P Williams, J.E McGowan, F.C Tenover. (2002) Validation of Vitek version 7.01 software for testing staphylococci against vancomycin. Diagnostic Microbiology and Infectious Disease 43:2, 135-140
CrossRef107
Soo-Whan KIM, Il-Moo CHANG, Ki-Bong OH. (2002) Inhibition of the Bacterial Surface Protein Anchoring Transpeptidase Sortase by Medicinal Plants.. Bioscience, Biotechnology, and Biochemistry 66:12, 2751-2754
CrossRef108
Chi Sing Lee, Debra A Allwine, Michael R Barbachyn, Kevin C Grega, Lester A Dolak, Charles W Ford, Randy M Jensen, Eric P Seest, Judith C Hamel, Ronda D Schaadt, Douglas Stapert, Betty H Yagi, Gary E Zurenko, Michael J Genin. (2001) Carbon–carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria. Bioorganic & Medicinal Chemistry 9:12, 3243-3253
CrossRef109
Yeon-Joon Park, Jung Jun Park, Seung-Ok Lee, Eun-Jee Oh, Byung Kee Kim. (2001) Low-level resistance to glycopeptides amongst staphylococcus species: Surveillance in a university hospital and evaluation of a vancomycin screening agar. Diagnostic Microbiology and Infectious Disease 41:3, 155-159
CrossRef110
Maite Garrouste‐Orgeas, Jean‐Francois Timsit, Hatem Kallel, Adel Ben Ali, Marie Francoise Dumay, Benedicte Paoli, Benoit Misset, Jean Carlet. (2001) Colonization With Methicillin‐Resistant Staphylococcus aureus in ICU Patients: Morbidity, Mortality, and Glycopeptide Use • . Infection Control and Hospital Epidemiology 22:11, 687-692
CrossRef111
Keiichi Hiramatsu. (2001) Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. The Lancet Infectious Diseases 1:3, 147-155
CrossRef112
D. Furuya, A. Yagihashi, N. Uehara, T. Yajima, D. Kobayashi, N. Watanabe. (2001) Genotype Analysis of Methicillin‐Resistant Staphylococcus aureus With and Without Reduced Susceptibility to Vancomycin Using Pulsed‐Field Gel Electrophoresis • . Infection Control and Hospital Epidemiology 22:9, 536-538
CrossRef113
A Nasim, M.M Thompson, A.R Naylor, P.R.F Bell, N.J.M London. (2001) The Impact of MRSA on Vascular Surgery. European Journal of Vascular and Endovascular Surgery 22:3, 211-214
CrossRef114
Ferenc Rozgonyi, Eszter Ostorházy, Csaba L. Maródi, et al.. (2001) Resitance to b lactams and glycopeptides in staphylococci and sterptococci (A review). Acta Microbiologica et Immunologica Hungarica 48:3, 359-391
CrossRef115
H. M. Ziglam, R. G. Finch. (2001) Limitations of presently available glycopeptides in the treatment of Gram-positive infection. Clinical Microbiology and Infection 7:4, 53-65
CrossRef116
J. Linares. (2001) The VISA/GISA problem: therapeutic implications. Clinical Microbiology and Infection 7:4, 8-15
CrossRef117
J. Carratala. (2001) Role of antibiotic prophylaxis for the prevention of intravascular catheter-related infection. Clinical Microbiology and Infection 7:4, 83-90
CrossRef118
Geraldo A. Oliveira, Adriana M. Dell’Aquila, Rita L. Masiero, Carlos E. Levy, Marcia S. Gomes, Longzhu Cui, Keiichi Hiramatsu, Elsa M. Mamizuka. (2001) Isolation in Brazil of Nosocomial Staphylococcus aureus with Reduced Susceptibility to Vancomycin • . Infection Control and Hospital Epidemiology 22:7, 443-448
CrossRef119
Joseph R. Lentino. (2001) Nosocomial pneumonia: More than just ventilator-associated. Current Infectious Disease Reports 3:3, 266-273
CrossRef120
A. Peschel, R. W. Jack, M. Otto, L. V. Collins, P. Staubitz, G. Nicholson, H. Kalbacher, W. F. Nieuwenhuizen, G. Jung, A. Tarkowski, K. P.M. van Kessel, J. A.G. van Strijp. (2001) Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with L-Lysine. Journal of Experimental Medicine 193:9, 1067-1076
CrossRef121
M. E. Reverdy, S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, G. Lina, F. Vandenesch, J. Etienne. (2001) Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clinical Microbiology and Infection 7:5, 267-272
CrossRef122
Maria Bodi, Carmen Ardanuy, Jordi Rello. (2001) Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Critical Care Medicine 29:Supplement, N82-N86
CrossRef123
Jerome J. Schentag. (2001) Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Critical Care Medicine 29:Supplement, N100-N107
CrossRef124
A.R. Naylor, P.D. Hayes, S. Darke. (2001) A Prospective Audit of Complex Wound and Graft Infections in Great Britain and Ireland: the Emergence of MRSA. European Journal of Vascular and Endovascular Surgery 21:4, 289-294
CrossRef125
Y.Jerold Gordon. (2001) Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes?11(Disclosure: Consultant to CibaVision-Novartis). American Journal of Ophthalmology 131:3, 371-376
CrossRef126
Debra D. Poutsiaka. (2001) Antimicrobial Resistance in the Chronically Critically Ill Patient. Clinics in Chest Medicine 22:1, 87-103
CrossRef127
Mohamed G. Atta, Joseph A. Eustace, Xiaoyan Song, Trish M. Perl, Paul J. Scheel. (2001) Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney International 59:2, 718-724
CrossRef128
M.-C. Roghmann, A. Siddiqui, K. Plaisance, H. Standiford. (2001) MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. Journal of Hospital Infection 47:2, 98-103
CrossRef129
Lawrence Goldberg, Michelle Clemenger, Berge Azadian, Edwina A. Brown. (2001) Initial Treatment of Peritoneal Dialysis Peritonitis Without Vancomycin With a Once-Daily Cefazolin-Based Regimen. American Journal of Kidney Diseases 37:1, 49-55
CrossRef130
R. A. Weinstein, S. K. Fridkin. (2001) Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to Know. Clinical Infectious Diseases 32:1, 108-115
CrossRef131
Franco Paradisi, Giampaolo Corti, Daniela Messeri. (2001) ANTISTAPHYLOCOCCAL (MSSA, MRSA, MSSE, MRSE) ANTIBIOTICS. Medical Clinics of North America 85:1, 1-17
CrossRef132
FARID M. HUSSAIN, SUSAN BOYLE-VAVRA, CINDY D. BETHEL, ROBERT S. DAUM. (2000) Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. The Pediatric Infectious Disease Journal 19:12, 1163-1166
CrossRef133
P. Pina, C. Marliere, F. Vandenesch, J.-P. Bedos, J. Etienne, P.-Y. Allouch. (2000) An Outbreak of Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides in a French General Hospital. Clinical Infectious Diseases 31:5, 1306-1308
CrossRef134
Thomas A. Golper, Gerald Schulman, Erika M. C. D'agata. (2000) Indications for Vancomycin in Dialysis Patients. Seminars in Dialysis 13:6, 389-392
CrossRef135
Beth Piraino. (2000) Staphylococcus Aureus Infections in Dialysis Patients: Focus on Prevention. ASAIO Journal 46:6, S13-S17
CrossRef136
Erica J. Larson, Janetta R. Hakovirta, Hong Cai, James H. Jett, Stefan Burde, Richard A. Keller, Babetta L. Marrone. (2000) Rapid DNA fingerprinting of pathogens by flow cytometry. Cytometry 41:3, 203-208
CrossRef137
David A. Hunstad, Joseph W. St. Geme. (2000) STAPHYLOCOCCUS AUREUS WITH REDUCED SUSCEPTIBILITY TO GLYCOPEPTIDE ANTIBIOTICS. The Pediatric Infectious Disease Journal 19:11, 1093-1095
CrossRef138
H. A. Moss, S. E. Tebbs, M. H. Faroqui, T. Herbst, J. L. Isaac, J. Brown, T. S. J. Elliott. (2000) A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. European Journal of Anaesthesiology 17:11, 680-687
CrossRef139
Yasuteru Sugino, Yoshitsugu Iinumab, Satoshi Ichiyama, Yuji Ito, Saburo Ohkawa, Nobuo Nakashima, Kaoru Shimokata, Yoshinori Hasegawa. (2000) In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease 38:3, 159-167
CrossRef140
Marin H. Kollef, Suzanne Ward, Glenda Sherman, Donna Prentice, Robyn Schaiff, Way Huey, Victoria J. Fraser. (2000) Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Critical Care Medicine 28:10, 3456-3464
CrossRef141
Ulrich Vogel, Heike Claus. (2000) The evolution of human pathogens: examples and clinical implications. International Journal of Medical Microbiology 290:6, 511-518
CrossRef142
E. Cercenado. (2000) Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem?. Clinical Microbiology and Infection 6:10, 517-518
CrossRef143
J. Burnie, R. Matthews, A. Jiman-Fatami, P. Gottardello, S. Hodgetts, S. D'arcy. (2000) Analysis of 42 Cases of Septicemia Caused by an Epidemic Strain of Methicillin-Resistant Staphylococcus aureus: Evidence of Resistance to Vancomycin. Clinical Infectious Diseases 31:3, 684-689
CrossRef144
M. H. Kollef. (2000) Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Clinical Infectious Diseases 31:Supplement 4, S131-S138
CrossRef145
Michael J Genin. (2000) Recent progress with oxazolidinone antibacterial agents. Expert Opinion on Therapeutic Patents 10:9, 1405-1414
CrossRef146
James T.C. Li, Patricia J. Markus, Douglas R. Osmon, Lynn Estes, Virginia A. Gosselin, Arlen D. Hanssen. (2000) Reduction of Vancomycin Use in Orthopedic Patients With a History of Antibiotic Allergy. Mayo Clinic Proceedings 75:9, 902-906
CrossRef147
Kornelis A. Poelstra, Nazir A. Barekzi, Jeffrey B. Slunt, Thomas C. Schuler, David W. Grainger. (2000) Surgical Irrigation with Pooled Human Immunoglobulin G to Reduce Post-Operative Spinal Implant Infection. Tissue Engineering 6:4, 401-411
CrossRef148
K. A. Poelstra, H. C. van der Mei, B. Gottenbos, D. W. Grainger, J. R. van Horn, H. J. Busscher. (2000) Pooled human immunoglobulins reduce adhesion ofPseudomonas aeruginosa in a parallel plate flow chamber. Journal of Biomedical Materials Research 51:2, 224-232
CrossRef149
Keith S. Kaye, Henry S. Fraimow, Elias Abrutyn. (2000) PATHOGENS RESISTANT TO ANTIMICROBIAL AGENTS. Infectious Disease Clinics of North America 14:2, 293-319
CrossRef150
Patrick J. Loll, Paul H. Axelsen. (2000) T
HE STRUCTURAL BIOLOGY OF MOLECULAR RECOGNITION BY VANCOMYCIN . Annual Review of Biophysics and Biomolecular Structure 29:1, 265-289
CrossRef151
Tammy S. Lundstrom, Jack D. Sobel. (2000) ANTIBIOTICS FOR GRAM-POSITIVE BACTERIAL INFECTIONS. Infectious Disease Clinics of North America 14:2, 463-474
CrossRef152
J. H. Jorgensen, M. J. Ferraro. (2000) Antimicrobial Susceptibility Testing: Special Needs for Fastidious Organisms and Difficult-to-Detect Resistance Mechanisms. Clinical Infectious Diseases 30:5, 799-808
CrossRef153
Robert E. Eckart, Duane R. Hospenthal, Joel T. Fishbain. (2000) Response of Complicated Methicillin-Resistant Staphylococcus aureus Endocarditis to the Addition of Trovafloxacin. Pharmacotherapy 20:5, 589-592
CrossRef154
Samson Sai-Yin Wong, Tak-Keung Ng, Wing-Cheong Yam, Dominic Ngai-Chong Tsang, Patrick Chiu-Yat Woo, Samuel Ka-Shun Fung, Kwok-Yung Yuen. (2000) Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagnostic Microbiology and Infectious Disease 36:4, 261-268
CrossRef155
UNKNOWN. (2000) Full Length Article. Annales Françaises d’Anesthésie et de Réanimation 19:3, 177-187
CrossRef156
Abinash Virk, James M. Steckelberg. (2000) Clinical Aspects of Antimicrobial Resistance. Mayo Clinic Proceedings 75:2, 200-214
CrossRef157
A Virk, J M Steckelberg. (2000) Clinical aspects of antimicrobial resistance.. Mayo Clinic Proceedings 75:2, 200-214
CrossRef158
Kevin Green, Gerald Schulman, David W. Haas, William Schaffner, Erika M.C. D'Agata. (2000) Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. American Journal of Kidney Diseases 35:1, 64-68
CrossRef159
Kieren A. Marr. (2000) Staphylococcus aureus Bacteremia in Patients Undergoing Hemodialysis. Seminars in Dialysis 13:1, 23-29
CrossRef160
Reida El Oakley, Khalid Al Nimer, Emad Bukhari. (2000) Is the use of topical vancomycin to prevent mediastinitis after cardiac surgery justified?. The Journal of Thoracic and Cardiovascular Surgery 119:1, 190-191
CrossRef161
I. SANTOS SANCHES, R. MATO, H. DE LENCASTRE, A. TOMASZ. (2000) Patterns of Multidrug Resistance among Methicillin-Resistant Hospital Isolates of Coagulase-Positive and Coagulase-Negative Staphylococci Collected in the International Multicenter Study RESIST in 1997 and 1998. Microbial Drug Resistance 6:3, 199-211
CrossRef162
ALEX VAN BELKUM. (2000) Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Strains: State of Affairs and Tomorrow's Possibilities. Microbial Drug Resistance 6:3, 173-188
CrossRef163
M. AIRES DE SOUSA, H. DE LENCASTRE, I. SANTOS SANCHES, K. KIKUCHI, K. TOTSUKA, A. TOMASZ. (2000) Similarity of Antibiotic Resistance Patterns and Molecular Typing Properties of Methicillin-Resistant Staphylococcus aureus Isolates Widely Spread in Hospitals in New York City and in a Hospital in Tokyo, Japan. Microbial Drug Resistance 6:3, 253-258
CrossRef164
RICHARD B. ROBERTS, MARILYN CHUNG, HERMINIA DE LENCASTRE, JUDIE HARGRAVE, ALEXANDER TOMASZ, DAVID P. NICOLAU, JOSEPH F. JOHN, OKSANA KORZENIOWSKI. (2000) Distribution of Methicillin-Resistant Staphylococcus aureus Clones Among Health Care Facilities in Connecticut, New Jersey, and Pennsylvania. Microbial Drug Resistance 6:3, 245-251
CrossRef165
DANIEL J. DIEKEMA, MICHAEL A. PFALLER, JOHN TURNIDGE, JAN VERHOEF, JAN BELL, AD C. FLUIT, GARY V. DOERN, RONALD N. JONES. (2000) Genetic Relatedness of Multidrug-Resistant, Methicillin (Oxacillin)-Resistant Staphylococcus aureus Bloodstream Isolates from SENTRY Antimicrobial Resistance Surveillance Centers Worldwide, 1998. Microbial Drug Resistance 6:3, 213-221
CrossRef166
Tarek Msadek. (2000) Stress and sensitivity. Trends in Microbiology 8:1, 10-11
CrossRef167
Diane Franchi, Michael W. Climo, Alice H. M. Wong, Michael B. Edmond, Richard P. Wenzel. (1999) Seeking Vancomycin Resistant Staphylococcus aureus among Patients with Vancomycin‐Resistant Enterococci. Clinical Infectious Diseases 29:6, 1566-1568
CrossRef168
(1999) Global Consensus Conference: Final recommendations. American Journal of Infection Control 27:6, 503-513
CrossRef169
Haraga, Isao, Nomura, Shuichi, Nagayama, Ariaki, . (1999) The Effects of Vancomycin and β-Lactam Antibiotics on Vancomycin-Resistant Staphylococcus aureus. New England Journal of Medicine 341:21, 1624-1624
Full Text170
Harald Labischinski, Lars Johannsen. (1999) Cell wall targets in methicillin-resistant staphylococci. Drug Resistance Updates 2:5, 319-325
CrossRef171
Gian Carlo Schito, Raymond Auckenthaler, Anna Marchese, Adolf Bauernfeind. (1999) European survey of glycopeptide susceptibility in Staphylococcus spp.. Clinical Microbiology and Infection 5:9, 547-553
CrossRef172
Mark P. Wilhelm, Lynn Estes. (1999) Vancomycin. Mayo Clinic Proceedings 74:9, 928-935
CrossRef173
K. C. Nicolaou, Christopher N. C. Boddy, Stefan Bräse, Nicolas Winssinger. (1999) Chemie, Biologie und medizinische Anwendungen der Glycopeptid-Antibiotika. Angewandte Chemie 111:15, 2230-2287
CrossRef174
John A. Jernigan. (1999) Glycopeptide resistance in Staphylococcus aureus. Current Infectious Disease Reports 1:4, 317-318
CrossRef175
Alexander Tomasz. (1999) The challenge of multiresistant Streptococcus pneumoniae: international initiatives in day-care centers and the use of molecular epidemiologic techniques. Clinical Microbiology and Infection 5, S64-S68
CrossRef176
Jan Verhoef. (1999) Surveillance of antibiotic resistance. Current Opinion in Infectious Diseases 12:4, 321-326
CrossRef177
Chesley L. Richards, William R. Jarvis. (1999) Lessons from recent nosocomial epidemics. Current Opinion in Infectious Diseases 12:4, 327-334
CrossRef178
Kumthorn Malathum, Barbara E. Murray. (1999) Vancomycin-resistant enterococci: recent advances in genetics, epidemiology and therapeutic options. Drug Resistance Updates 2:4, 224-243
CrossRef179
Robert P. Rapp. (1999) Antimicrobial Resistance in Gram-Positive Bacteria: The Myth of the MIC. Pharmacotherapy 19:8 Part 2, 112S-119S
CrossRef180
Barry M. Farr. (1999) Methicillin-resistant Staphylococcus aureus infections. Current Infectious Disease Reports 1:4, 328-333
CrossRef181
(1999) Vancomycin Resistance in Staphylococcus aureus. New England Journal of Medicine 341:3, 207-208
Full Text182
J.M.T Hamilton-Miller, S Shah. (1999) Disorganization of cell division of methicillin-resistant Staphylococcus aureus by a component of tea ( Camellia sinensis ): a study by electron microscopy. FEMS Microbiology Letters 176:2, 463-469
CrossRef183
Waldvogel, Francis A., . (1999) New Resistance in Staphylococcus aureus. New England Journal of Medicine 340:7, 556-557
Full Text184
KRZYSZTOF SIERADZKI, SHANG WEI WU, ALEXANDER TOMASZ. (1999) Inactivation of the Methicillin Resistance Gene mecA in Vancomycin-Resistant Staphylococcus aureus. Microbial Drug Resistance 5:4, 253-257
CrossRef
- Letters
